☆ 4.5 Article

A skewed ratio of free light chains is more common in patients with late-onset than early-onset myasthenia gravis

IMMUNOLOGY LETTERS (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders

Maartje G. Huijbers et al.

Summary: Immunosuppressive treatments for autoimmune neuromuscular junction disorders are available, but a cure has not yet been found. Recent advances in understanding the structure and function of the neuromuscular junction have provided insight into the pathophysiology of these diseases and laid the foundation for the development of new therapeutic strategies.

LANCET NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders

Anna Rostedt Punga et al.

Summary: Autoimmune neuromuscular junction disorders are rare, with myasthenia gravis being increasingly recognized in older individuals. Various diagnostic methods, such as serological antibody, electrophysiological, imaging, and pharmacological tests, are available for these disorders. Determining if the disease is paraneoplastic is important for prognosis. However, objective biomarkers are needed to predict the disease course of myasthenia gravis and Lambert-Eaton myasthenic syndrome.

LANCET NEUROLOGY (2022)

Add to Collection

Article Medical Laboratory Technology

The role of serum free light chain as biomarker of Myasthenia Gravis

Caterina Maria Gambino et al.

Summary: This study evaluated the potential role of free light chains (FLC) as biomarkers for myasthenia gravis (MG) and found that increased FLC levels can serve as diagnostic biomarkers for MG.

CLINICA CHIMICA ACTA (2022)

Add to Collection

Article Pathology

Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy

Joona Sarkkinen et al.

Summary: This study used digital pathology to explore the predictive ability of thymic histopathology in non-thymomatous myasthenia gravis (NTMG). The results showed differences in thymic histology between early-onset MG (EOMG) and late-onset MG (LOMG), and the impact of thymic changes on thymectomy outcomes. The number of ectopic germinal centers (eGC) was found to be a valuable predictor for post-thymectomy outcomes in EOMG patients.

MODERN PATHOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study

Ruth Chia et al.

Summary: This study identified genetic risk loci associated with myasthenia gravis through a genome-wide association study and demonstrated different genetic risk factors between early-onset and late-onset cases. Genetic correlation analysis also revealed a genetic link between myasthenia gravis and other autoimmune diseases.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Article Cell Biology

Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production

Zhicui Liu et al.

Summary: The study demonstrates the diverse roles of CD40-CD40L and ICOS-ICOSL in cell adhesion and IgG/IgM production during CD4+ T-B cell interactions, with ICOS-ICOSL ligation more likely to be engaged in cell adhesion while CD40-CD40L provides indispensable signal for B cell differentiation and IgG/IgM production. This information might be helpful for understanding the pathogenesis of SLE.

CELLULAR IMMUNOLOGY (2021)

Add to Collection

Article Medical Laboratory Technology

Serum free light chain reference intervals in an Optilite and their influence on clinical guidelines

Luis J. Morales-Garcia et al.

Summary: This study established new reference intervals and diagnostic ranges for free light chain analysis on the Optilite turbidimeter, showing significant differences from the existing guidelines. Validation with samples of polyclonal hypo- and hypergammaglobulinemia confirmed the new diagnostic range's efficacy as a monoclonal proliferation index.

CLINICAL BIOCHEMISTRY (2021)

Add to Collection

Review Medical Laboratory Technology

Roles of matrix metalloproteinase-7 (MMP-7) in cancer

Hai-Yang Liao et al.

Summary: MMP-7 is a crucial proteolytic enzyme involved in regulating various human pathophysiological processes, especially in the occurrence and development of cancers. It could serve as a potential tumor biomarker and therapeutic target, providing new diagnostic and prognostic considerations for cancer patients.

CLINICAL BIOCHEMISTRY (2021)

Add to Collection

Review Genetics & Heredity

Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis

Jinwei Zhang et al.

Summary: Late-onset non-thymomatous myasthenia gravis (NTMG) patients have a lower likelihood of achieving clinical stable remission after thymectomy compared to early-onset patients. Thymectomy in late-onset NTMG does not show any benefits in terms of clinical stable remission/pharmacological remission when compared to conservative treatments. Further research is needed to determine the appropriate therapeutic strategies for late-onset NTMG patients.

ORPHANET JOURNAL OF RARE DISEASES (2021)

Add to Collection

Article Clinical Neurology

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset

Elena Cortes-Vicente et al.

NEUROLOGY (2020)

Add to Collection

Review Immunology

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics

Konstantinos Lazaridis et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Clinical Neurology

High kappa free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis

Adi Wilf-Yarkoni et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Review Oncology

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy

Cinzia Solinas et al.

ESMO OPEN (2020)

Add to Collection

Article Clinical Neurology

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

Gil I. Wolfe et al.

LANCET NEUROLOGY (2019)

Add to Collection

Review Oncology

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

Evelina Martinenaite et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

Add to Collection

Article Medical Laboratory Technology

Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study

Steven W. Cotten et al.

CLINICAL BIOCHEMISTRY (2018)

Add to Collection

Article Immunology

Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients

Umberto Basile et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2018)

Add to Collection

Article Multidisciplinary Sciences

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients

Carl Johan Molin et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Review Medicine, Research & Experimental

The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases

Mojgan Esparvarinha et al.

BIOMEDICINE & PHARMACOTHERAPY (2017)

Add to Collection

Article Immunology

Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis

Guher Saruhan-Direskeneli et al.

CLINICAL IMMUNOLOGY (2016)

Add to Collection

Review Medicine, General & Internal

Myasthenia Gravis

Nils E. Gilhus

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Multidisciplinary Sciences

Changes in inflammatory cytokine networks in myasthenia gravis

Akiyuki Uzawa et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Review Clinical Neurology

Myasthenia gravis: subgroup classification and therapeutic strategies

Nils Erik Gilhus et al.

LANCET NEUROLOGY (2015)

Add to Collection

Review Clinical Neurology

Myasthenia gravis and risks for comorbidity

N. E. Gilhus et al.

EUROPEAN JOURNAL OF NEUROLOGY (2015)

Add to Collection

Article Immunology

Serum cytokine and chemokine profiles in patients with myasthenia gravis

A. Uzawa et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)

Add to Collection

Review Immunology

Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms

Sonia Berrih-Aknin et al.

JOURNAL OF AUTOIMMUNITY (2014)

Add to Collection

Article Clinical Neurology

Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker

Tanel Punga et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)

Add to Collection

Review Immunology

The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes

Alexander Marx et al.

AUTOIMMUNITY REVIEWS (2013)

Add to Collection

Article Medical Laboratory Technology

Serum free light chain reference values: A critical approach

Sara Altinier et al.

CLINICAL BIOCHEMISTRY (2013)

Add to Collection

Article Clinical Neurology

Risk for Myasthenia Gravis Maps to a 151Pro→Ala Change in TNIP1 and to Human Leukocyte Antigen-B*08

Peter K. Gregersen et al.

ANNALS OF NEUROLOGY (2012)

Add to Collection

Article Clinical Neurology

Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis

Tomoko Masuda et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)

Add to Collection

Article Multidisciplinary Sciences

Late Onset Myasthenia Gravis Is Associated with HLA DRB1*15:01 in the Norwegian Population

Angelina H. Maniaol et al.

PLOS ONE (2012)

Add to Collection

Article Hematology

Serum free light chain analysis

Matthew S. Davids et al.

AMERICAN JOURNAL OF HEMATOLOGY (2010)

Add to Collection

Review Clinical Neurology

A systematic review of population based epidemiological studies in Myasthenia Gravis

Aisling S. Carr et al.

BMC NEUROLOGY (2010)

Add to Collection

Review Multidisciplinary Sciences

The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine

Toshikazu Nakamura et al.

PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2010)

Add to Collection

Review Clinical Neurology

Lifetime course of myasthenia gravis

David Grob et al.

MUSCLE & NERVE (2008)

Add to Collection

Article Hematology

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

SV Rajkumar et al.

BLOOD (2005)

Add to Collection

Article Clinical Neurology

Associated conditions in myasthenia gravis:: response to thyrnectorny

JF Téllez-Zenteno et al.

EUROPEAN JOURNAL OF NEUROLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.